Literature DB >> 19446292

Chymase activity is closely related with plaque vulnerability in a hamster model of atherosclerosis.

Tao Guo1, Wen Qiang Chen, Cheng Zhang, Yu Xia Zhao, Yun Zhang.   

Abstract

OBJECTIVE: To test the hypothesis that stimulation of chymase secretion may contribute to plaque vulnerability and inhibition of chymase activity may enhance plaque stability. METHODS AND
RESULTS: Sixty eight-week-old male Syrian golden hamsters were randomly divided into normal control group, high-cholesterol (HC) treated group, HC+ovalbumin treated group and HC+tranilast treated group. The normal control group received a normal diet while the other three intervention groups received a high-cholesterol diet for 15 weeks. Hamsters in the HC+ovalbumin treated group underwent transcatheter pharmacological triggering at the end of week 15 after antigen sensitization and those in the HC+tranilast treated group were given tranilast intragastrically for 3 weeks before euthanasia. Serological, ultrasonographic, pathologic, immunohistochemical, and gene expression studies were performed in all animals. The total number of mast cells, proportion of degranulated mast cells and the number of extracellular granules in plaques, the apoptosis rate of vascular smooth cells, the local activities of chymase, the concentration of Ang II and the expression levels of inflammatory markers as well as plaque vulnerability index all increased significantly in HC+ovalbumin treated group, but remarkably decreased in HC+tranilast treated group, in comparison with the HC treated group. These results suggest that stimulation of chymase secretion contributes to plaque vulnerability while inhibition of chymase activity enhances plaque stability. We conclude that chymase activity provides a promising therapeutic target in the stabilization of atherosclerotic plaques.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19446292     DOI: 10.1016/j.atherosclerosis.2009.04.014

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  8 in total

Review 1.  Chymase inhibition as a pharmacological target: a role in inflammatory and functional gastrointestinal disorders?

Authors:  S Heuston; N P Hyland
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

2.  Expression and activity levels of chymase in mast cells of burn wound tissues increase during the healing process in a hamster model.

Authors:  Xianglin Dong; Tao Xu; Shaolin Ma; Hao Wen
Journal:  Exp Ther Med       Date:  2015-04-14       Impact factor: 2.447

3.  Efficacy of antihistamines on mortality in patients receiving maintenance hemodialysis: an observational study using propensity score matching.

Authors:  Kiyotsugu Omae; Masao Yoshikawa; Hiroshi Sakura; Kosaku Nitta; Tetsuya Ogawa
Journal:  Heart Vessels       Date:  2017-05-16       Impact factor: 2.037

Review 4.  Mast cells in human and experimental cardiometabolic diseases.

Authors:  Guo-Ping Shi; Ilze Bot; Petri T Kovanen
Journal:  Nat Rev Cardiol       Date:  2015-08-11       Impact factor: 32.419

Review 5.  Mast cells as effectors in atherosclerosis.

Authors:  Ilze Bot; Guo-Ping Shi; Petri T Kovanen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-08-07       Impact factor: 8.311

Review 6.  Mast cells: an expanding pathophysiological role from allergy to other disorders.

Authors:  Preet Anand; Baldev Singh; Amteshwar Singh Jaggi; Nirmal Singh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-05-06       Impact factor: 3.000

7.  Detection of high-risk atherosclerotic plaques with ultrasound molecular imaging of glycoprotein IIb/IIIa receptor on activated platelets.

Authors:  Shengcun Guo; Shuxin Shen; Junfen Wang; He Wang; Meiyu Li; Ying Liu; Fanfan Hou; Yulin Liao; Jianping Bin
Journal:  Theranostics       Date:  2015-02-05       Impact factor: 11.556

Review 8.  Spotlight on NLRP3 Inflammasome: Role in Pathogenesis and Therapies of Atherosclerosis.

Authors:  Chunteng Jiang; Santuan Xie; Guang Yang; Ningning Wang
Journal:  J Inflamm Res       Date:  2021-12-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.